<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413201</url>
  </required_header>
  <id_info>
    <org_study_id>AFAMOSI</org_study_id>
    <secondary_id>2019-002197-31</secondary_id>
    <nct_id>NCT04413201</nct_id>
  </id_info>
  <brief_title>AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC</brief_title>
  <official_title>AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Hopp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open label Phase IV trial will be performed in patients with a diagnosis of&#xD;
      advanced NSCLC (non-squamous cell histology), harboring EGFR mutation positive but T790M&#xD;
      Mutation negative, who have no previous chemotherapy for metastatic NSCLC. Neoadjuvant or&#xD;
      adjuvant systemic treatments had to be finished at least (≥) 6 months before study inclusion.&#xD;
      In conclusion, this study is investigating the important clinical question whether tumor&#xD;
      growth and long term overall survival for a patient is better controlled in a specific&#xD;
      treatment sequence of different EGFR-inhibitors. Patients will be treated with registered&#xD;
      compounds according to their label in both treatment arms. Thus, all patients will get an&#xD;
      effective treatment regimen and patients who progressed on afatinib, and who developed a&#xD;
      T790M mutation will be treated subsequently with osimertinib. Those who progressed under&#xD;
      osimertinib or under afatinib without T790M mutation will be treated according to the current&#xD;
      treatment guidelines with Investigator´s choice of active therapy (ICT) including but not&#xD;
      limited to platin doublet chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to EGFR-TKI failure within 24 months for afatinib followed by osimertinib in T790Mpositive group vs osimertinib</measure>
    <time_frame>24 months</time_frame>
    <description>The main objective is to investigate whether the time to EGFR-TKI failure at 24 months is better for the treatment sequence of afatinib followed by osimertinib in the T790M positive group compared to osimertinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to EGFR-TKI failure (afatinib versus osimertinib)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from randomization until ICT is indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS: afatinib followed by osimertinib or ICT vs osimertinib followed by ICT)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from randomization until disease progression according to RECIST or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Survival Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>12 months</time_frame>
    <description>CR+PR according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>24 months</time_frame>
    <description>CR+PR according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>CR+PR+SD according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>CR+PR+SD according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse Events as assessed by intensity of the of the adverse events and the causal relation to trial medication Intensity/Severity: investigator will use the following definitions of severity in accordance with National Cancer Institute common terminology criteria for adverse events, CTCAE, version 5.0; assessment of the relationship of an adverse event to the administration of study drug is a clinical decision by the investigator Institute common terminology criteria for adverse events, CTCAE, version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom control assessed by patient-reported quality of life (QoL): EQ-5D</measure>
    <time_frame>24 months</time_frame>
    <description>patient-reported quality of life assessed by European Quality of Life 5 Dimensions Questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom control assessed by patient-reported quality of life (QoL): EORTC QLQ-C30</measure>
    <time_frame>24 months</time_frame>
    <description>patient-reported quality of life assessed by Questionnaire of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom control assessed by patient-reported quality of life (QoL): EORTC QLQ-LC29</measure>
    <time_frame>24 months</time_frame>
    <description>EORTC QLQ-LC29</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Non-squamous NSCLC</condition>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Afatinib followed by osimertinib or ICT depending on T790M status</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osimertinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Osimertinib followed by ICT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib followed by osimertinib or ICT</description>
    <arm_group_label>Afatinib</arm_group_label>
    <other_name>Osimertinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib followed by ICT</description>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_label>Osimertinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-squamous NSCLC harboring EGFR mutation positive but T790M&#xD;
             mutation negative by local testing&#xD;
&#xD;
          -  Unresectable stage UICC ≥ IIIb or metastatic stage UICC IV disease&#xD;
&#xD;
          -  TKI naïve for metastatic NSCLC, neoadjuvant or adjuvant chemotherapy allowed&#xD;
&#xD;
          -  At least one evaluable lesion according to RECIST v1.1&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status 0 - 2&#xD;
&#xD;
          -  Adequate organ function, defined as all of the following:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1500/mm3. (ANC &gt; 1000/mm3 may be considered in&#xD;
                  special circumstances such as benign cyclical neutropenia as judged by the&#xD;
                  investigator and in discussion with the coordinating investigator)&#xD;
&#xD;
               2. Platelet count ≥ 75,000/mm3&#xD;
&#xD;
               3. Estimated glomerular filtration rate (eGFR) &gt; 45 ml/min/1.73 m2 according to the&#xD;
                  Cockcroft-Gault formula d. If history of cardiac comorbidity: Left ventricular&#xD;
                  function with resting ejection fraction ≥ 50% or above the institutional lower&#xD;
                  limit of normal (LLN)&#xD;
&#xD;
             e. Total Bilirubin ≤ 1.5 times upper limit of normal (ULN), (if related to liver&#xD;
             metastases ≤ 3 times ULN). (Patients with Gilbert's syndrome total Bilirubin must be ≤&#xD;
             4 times institutional upper limit of normal) f. Aspartate amino transferase (AST) or&#xD;
             alanine amino transferase (ALT) ≤ 3 times the upper limit of normal (ULN) (if related&#xD;
             to liver metastases ≤ 5 times ULN)&#xD;
&#xD;
          -  Recovered from any previous therapy related toxicity to ≤ Grade 1 at before&#xD;
             randomization (except for stable sensory neuropathy ≤ Grade 2 and alopecia)&#xD;
&#xD;
          -  Written informed consen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any investigational drug within 30 days or hormonal anticancer treatment within 2&#xD;
             weeks prior to randomization (continued use of anti-androgens and/or gonadorelin&#xD;
             analogues for treatment of prostate cancer permitted)&#xD;
&#xD;
          -  T790M mutation positive tumors (by local testing)&#xD;
&#xD;
          -  Radiotherapy within 2 weeks prior to randomization, except as follows:&#xD;
&#xD;
               1. Palliative radiation to target organs other than chest may be allowed up to 1&#xD;
                  week prior to randomization&#xD;
&#xD;
               2. Single dose palliative treatment for symptomatic metastasis outside above&#xD;
                  allowance to be discussed with coordinating investigator prior to enrolling&#xD;
&#xD;
          -  Major surgery within 2 weeks before starting study treatment or scheduled for surgery&#xD;
             during the projected course of the study&#xD;
&#xD;
          -  Known hypersensitivity to afatinib or osimertinib or the excipients of any of the&#xD;
             trial drugs&#xD;
&#xD;
          -  History or presence of clinically relevant cardiovascular abnormalities such as&#xD;
&#xD;
               1. uncontrolled hypertension&#xD;
&#xD;
               2. congestive heart failure NYHA classification of ≥ 3&#xD;
&#xD;
               3. unstable angina or poorly controlled arrhythmia as determined by the investigator&#xD;
&#xD;
               4. Myocardial infarction within 6 months prior to randomization&#xD;
&#xD;
               5. Clinically important abnormalities in rhythm and conduction as measured by&#xD;
                  resting electrocardiogram (ECG) (e.g. QTc interval greater than 470 ms) or QTc&#xD;
                  interval prolongation with signs/symptoms of serious arrhythmia&#xD;
&#xD;
               6. Congenital long QT syndrome, congestive heart failure, electrolyte abnormalities,&#xD;
                  or intake of medicinal products that are known to prolong the QTc interval&#xD;
&#xD;
          -  Patients with a past or present medical history of&#xD;
&#xD;
               1. Interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that&#xD;
                  required steroid treatment, or any evidence of clinically active ILD&#xD;
&#xD;
               2. Any history of or concomitant condition that, in the opinion of the Investigator,&#xD;
                  would compromise the patient's ability to comply with the study or interfere with&#xD;
                  the evaluation of the efficacy and safety of the test drug&#xD;
&#xD;
               3. Any history or presence of poorly controlled gastrointestinal disorders that&#xD;
                  could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative&#xD;
                  colitis, chronic diarrhoea, malabsorption)&#xD;
&#xD;
               4. Known active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B&#xD;
                  DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or&#xD;
                  known HIV carrier&#xD;
&#xD;
               5. Previous or concomitant malignancies at other sites, except effectively treated&#xD;
                  non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in&#xD;
                  situ or effectively treated malignancy that has been in remission for more than 5&#xD;
                  years and is considered to be cured&#xD;
&#xD;
          -  Pregnancy and contraception:&#xD;
&#xD;
               1. Women who are pregnant, nursing, or who plan to become pregnant while in the&#xD;
                  trial&#xD;
&#xD;
               2. Women of child-bearing potential (WOCBP) and men who are able to father a child,&#xD;
                  unwilling to be abstinent or use highly effective methods of birth control that&#xD;
                  result in a low failure rate of less than 1% per year when used consistently and&#xD;
                  correctly beginning at informed consent, for the duration of study participation&#xD;
                  and for at least 2 months for females and 4 months for males after last dose&#xD;
&#xD;
          -  Requiring treatment with any of the prohibited concomitant medications protein&#xD;
             Inhibitors/Inductors CYP3A4/5 Inhibitors/Inductors that cannot be stopped for the&#xD;
             duration of trial participation or concomitant St. John's Wort&#xD;
&#xD;
          -  Uncontrolled brain metastases (Patients with brain or subdural metastases are not&#xD;
             eligible, unless they have completed local therapy (≤ 2 weeks apart from last&#xD;
             radiotherapy or radiosurgery) and have discontinued the use of corticosteroids,&#xD;
             anticonvulsants or have been on stable dose of corticosteroids (i.e. Dexamethasone ≤ 8&#xD;
             mg) for at least 4 weeks before starting study treatment. Any symptoms attributed to&#xD;
             brain metastases must be stable for at least 4 weeks before starting study treatment)&#xD;
             or Leptomeningeal carcinomatosis 11. Other contraindications to study treatment&#xD;
             (Investigators opinion) or legal incapacity or limited legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Wehler, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Gießen Marburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Ehrlich, Dr med</last_name>
    <phone>+49 6131 17</phone>
    <phone_ext>9945</phone_ext>
    <email>ehrich@izks-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Wehler, Prof Dr. med.</last_name>
    <phone>+49 641985</phone>
    <phone_ext>58544</phone_ext>
    <email>thomas.wehler@innere.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Ludwig-Maximilians-Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Tufmann, PD Dr. med</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>55393</phone_ext>
      <email>Amanda.tufman@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen Marburg</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wehler, Prof.Dr.</last_name>
      <phone>+49 641 985</phone>
      <phone_ext>58544</phone_ext>
      <email>thomas.wehler@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Grohe, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Sylke Kurz, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Ost</name>
      <address>
        <city>Bremen</city>
        <zip>28325</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Bethge, Dr med</last_name>
      <email>andre.bethge@gesundheitnord.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Hämato-Onkologie Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckart Laack, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Birte Andritzky, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Baraniskin, Dr med</last_name>
      <phone>+49 2381 589</phone>
      <phone_ext>1863</phone_ext>
      <email>alexander.baraniskin@valeo-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Allgäug gGmbH, Klinik für Pneumologie, c/o Klinik</name>
      <address>
        <city>Immenstadt</city>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schumann, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz Mbh</name>
      <address>
        <city>Konstanz</city>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Benkelmann, DR med</last_name>
    </contact>
    <contact_backup>
      <last_name>Albrecht Dix</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Kuon, Dr. med.</last_name>
      <phone>+49 7130</phone>
      <phone_ext>154207</phone_ext>
      <email>jonas.kuon@klinik-loewenstein.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schulz, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Maximilian V Malfertheiner, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Michael Hopp</investigator_full_name>
    <investigator_title>Head of Interdisciplinary Center for Clinical Studies (IZKS)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

